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ABSTRACT
MRI-guided focused ultrasound surgery (MRgFUS) is a minimally invasive treatment guided by the most sophisticated
imaging tool available in today’s clinical practice. Both the imaging and therapeutic sides of the equipment are based on
non-ionizing energy. This technique is a very promising option as potential treatment for several pathologies, including
musculoskeletal (MSK) disorders. Apart from clinical applications, MRgFUS technology is the result of long, heavy and
cumulative efforts exploring the effects of ultrasound on biological tissues and function, the generation of focused
ultrasound and treatment monitoring by MRI. The aim of this article is to give an updated overview on a “new”
interventional technique and on its applications for MSK and allied sciences.
MRI-GUIDED FOCUSED ULTRASOUND
SURGERY
The use of MRI to guide interventional procedures would
be desirable in a number of procedures thanks to its best
tissue identification and characterization features. MRI pro-
vides a superior window on anatomy and can be considered
a one-stop-source technique for pre-treatment and post-
treatment evaluations as well as for treatment planning, with
a complete spectrum of available imaging biomarkers;1
furthermore, MRI does not use ionizing radiation. The use
of MRI as guide for procedures in musculoskeletal (MSK)
diseases is particularly advantageous because of (a) the
epidemiological impact and distribution of these disorders,
from children to older adults; (b) specific features of MSK
pathology, which is often benign, or chronic, for the most
prevalent disorders; and (c) the need for multisession treat-
ment or retreatment in several conditions. On the contrary,
limitations are mainly related to costs and to compatible
materials (for both safety and artefacts).
From an historical point of view, ultrasound in medicine
was firstly employed for therapeutic purpose and later for
diagnostics. After the first experimentations performed by
the Curie brothers (and Joule) in the 19th century, Wood
and Loomis2 reported their experience on the effects of
ultrasound in 1927 and recognized how they could produce
permanent alterations in biological systems. The most
commonly known effect of the interaction between me-
chanical acoustic waves and biological system is thermal:
absorption of acoustic energy in a tissue leads to heat. More
recently, other effects on biological tissues (not related to
the thermic effect) were demonstrated to be potentially
useful in treating human pathology.3–5
In diagnostics, high-frequency and low-power ultrasound
are used in order to avoid permanent effects on the body,
whereas lower frequency and higher power ultrasound are
used for therapeutic applications in order to obtain po-
tential permanent effects. In more detail, observed effects
seem to be reversible and/or of potential benefit for tissue
biology at low power (;100mWcm22), whereas ultra-
sound can produce instant tissue necrosis at very high
power (;1000W cm22).3–5 Based on frequency and
power, ultrasound has been used for several applications in
medicine, such as: high frequency (1–3MHz), low power,
separation technology—ultrasonic standing waves; low
frequency (20–100 kHz), high/intermediate power, den-
tistry and surgery (scalpel, bone cutting), synthesis of
microcapsules for drug delivery; high frequency (1–3MHz) and
intermediate/low power, physiotherapy, bone healing, destruc-
tion of blood clots (sonothrombolysis), transdermal drug de-
livery (sonophoresis), improved drug intake in cells (sonoporation),
drug activation (sonodynamic therapy) and high-intensity focused
ultrasound (HIFU).3–5
Bursts of focused ultrasound energy are three orders of mag-
nitude more intense than diagnostic ultrasound. The use of
therapeutic focused ultrasound surgery (FUS) dates back to
1940s, born with the intent to destroy the tissue in a focal spot
inside the body. A major advantage of HIFU over other thermal
ablation techniques was in its capability of enabling rapid
heating of the target tissue volume without any percutaneous
insertion of probes or seriously affecting tissue along the ultra-
sound propagation path.
MRI-GUIDED FOCUSED ULTRASOUND SURGERY,
PRINCIPLES AND TECHNOLOGY
HIFU is currently considered as one of the most promising
therapeutic applications of ultrasound, although additional
knowledge is needed, with specific regard to the method of
targeting the tissue to be destroyed and monitoring the target
volume during the treatment.6–8
Therapeutic effects are obtained through both thermal and non-
thermal interaction mechanisms. Ultrasound can be used to
non-invasively produce different bioeffects via viscous heating,
acoustic cavitation or their combination. At low intensities,
acoustic streaming is likely to be significant, but at higher levels,
heating and acoustic cavitation usually predominate; for pres-
sures above a critical threshold, cavitation as the formation of
vapour cavities (“bubbles” or “voids”) occurs.9 In order to
manage these different effects, imaging methods are needed to
map temperature changes and/or cavitation activity.6–8
HIFU was initially guided by ultrasound imaging; however, there
were several limitations in identifying the target volume and in
overviewing the treatment region by using ultrasound, as well as
in monitoring the treated area during and after the procedure,
especially in bone applications.10,11
MRI was proposed as potential imaging guide in 1991 at the
University of Arizona.12 Experimental studies on animals were
reported for the first time at the International Conference of
Hyperthermic Oncology in 1992 and were subsequently
published.13,14 The first application on human subjects was
tested for breast fibroadenoma in 2001.15 The first commer-
cially available system (ExAblate 2000; InSightec, Tirat-Carmel,
Israel) was approved by European conformity (CE) in 2002 and
by the US Food and Drug Administration (FDA) in 2004,
mainly for the treatment of uterine fibroids.16 The acronyms
FUS and MRgFUS (MRI-guided focused ultrasound surgery)
were introduced to describe the most recent techniques asso-
ciated with MRI guidance. MRgFUS is totally based on “clean”
energy, both to treat and to guide. Radiologists approaching
MRgFUS should become familiar with concepts such as acous-
tic field, acoustic absorption, attenuation, reflection, aberration
and with spot/focal size, frequency, power, “sonication” time,
and thermal/mechanical effects, cavitation etc. “Sonication” is
the act of applying sound energy to agitate particles in a tissue.
This can be featured with different parameters to obtain dif-
ferent results on tissues. Focused ultrasound are typically
generated by a phased-array multielement transducer to pro-
duce a beam which enters the body from the skin surface,
passes through different layers and gets to the target, delivering
the majority of its energy there (Figure 1). Depending on the
absorption rate and depth of the target, and the features of the
tissues along the ultrasound propagation path (before the tar-
get), heating up to coagulative necrosis of the targeted tissue can
be obtained. On the other hand, energy not delivered in the near
field or in the target can still affect structures in the far field
(beyond the target). The true deposition of energy within the
target tissue depends not only on ultrasound parameters
(e.g. acoustic intensity, exposure time etc.) but also on tissue
features, structure and functional status.17–19 Intraoperative
MRI allows dynamic control of energy deposition using real-
time MRI thermometry1 (Figure 2). Through MR thermome-
try, it is possible to monitor the temperature in the target
volume in near real time and calculate the thermal dose re-
ceived by the treated region. Although several improvements
have been introduced even for ultrasound guide,20 MRI shows
a few advantages in terms of parameters of sonication (no need
for fast sonication/cavitation), panoramic view of the field of
treatment, excellent pre-/post-treatment evaluation and, as
mentioned above, of temperature monitoring during the energy
delivery.
In addition, prototypes of hybrid systems have also been
designed to better address the needs for intraoperative evalu-
ation of ultrasound effects, with combined ultrasound/MRI-
guided HIFU machines integrating an ultrasound imaging
array into a MRgFUS system, in order to simultaneously visu-
alize thermal and mechanical effects (localized cavitation activity
and temperature) via passive acoustic mapping and MR tem-
perature imaging.21,22
Given the wide-ranging applicability of HIFU, numerous ex-
tracorporeal and intracorporeal (e.g. transrectal, transuretral,
intravascular, interstitial etc.) devices have been designed to
optimize application-specific treatment deliver. Today, tools
tailored for different organs and clinical situations are avail-
able; brain, breast, prostate, abdominal organs and bone are
approached by using different devices in order to achieve the
best comfort and positioning of the patient as well as to obtain
an effective FUS therapy.23
Currently, the first manufacturer in the MRgFUS field is
InSightec with ExAblate series, followed by Philips Medical
Systems (Eindhoven, Netherlands) with Sonoalleve. Advanced
software interfaces have been developed and can be used in
clinical practice in order to optimize the treatment plan and to
improve the operator interaction and confidence with the
system; furthermore, several additional tools currently con-
tribute to enhance the safety and control of the procedure. In
particular, for MSK applications, an accurate registration of
pre-treatment CT and MR images can be obtained and can
be useful in the treatment of bone lesions, especially in
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challenging sites to be treated or if accurate information on
the extent, integrity and quality of the cortical bone are
required.24
MRgFUS is currently employed in several fields (such as on-
cology, urology, gynaecology and MSK, and in other branches
such as neurology and cardiovascular) at different levels, from
Figure 1. Conventional multielement phased-array transducer for MRI-guided focused ultrasound surgery applications including
bone (InSightec, Tirat Carmel, Israel). The transducer works to assure optimal and sharp focusing of the ultrasound beam,
depending on the target. The focusing ensures that significant energy delivery is only at the desired focal point and is low at other
locations, thus not impacting other tissues (a). The transducer may have a number of elements from piezoelectric materials that
oscillate upon application of an alternating voltage resulting in the generation of ultrasound waves, with a matching layer on it
(impedance matching) (b). RF, radiofrequency.
Figure 2. Screenshot of a MRI-guided focused ultrasound surgery workstation after “sonication”, during the treatment of a painful
bone metastasis from thyroid cancer in a 60-year-old female. The beam path is shown, with “near field” before the target (circle)
and “far field” beyond. Typically, in bone applications, the focus (cross) is set beyond the cortical surface target to exploit the high
absorption of the cortical bone. Areas/volumes covered and ablated by previous sonications are highlighted. The higher line shows
thermal images during sonication. The graph at the bottom right shows the evolution of temperature during sonication, and this can
be checked pixel by pixel.
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pre-clinical to clinical activity, and with variable results in terms
of safety and efficacy.1
MSK pathology is extremely common and involves the whole
spectrum of population with several relationships to other dis-
eases. Percutaneous treatments represent the modern surgical
perspective, with very competitive effectiveness and associated
cost drop, reduction of complication rate and rehabilitation
time. However, the majority of these procedures still required an
invasive approach, although less than traditional surgery, and
they are still guided by ionizing radiations in most cases.
MRgFUS offers several advantages in comparison with these
techniques, since it is a radiation-free technique not requiring
any surgical incision or invasive/mini-invasive approach; how-
ever, a large variety of technical, financial, clinical and practical
challenges must be overcome to allow MRgFUS to break
through into clinical practice and to make the transition from
a research curiosity to a clinical standard of care.25,26
MRGFUS, LESSONS LEARNED FROM NON-
MUSCULOSKELETAL APPLICATIONS
Clinical applications of HIFU were mainly focused on oncology;
over the past 15 years, a growing number of trials have examined
HIFU treatment of both benign and malignant tumours of the
prostate, breast, liver, pancreas, kidney, uterus, thyroid, para-
thyroid, brain, connective tissue and bone, and in some of these
emerging indications, HIFU potentially represents a serious al-
ternative or adjunct to current standard treatments, including
surgery, radiation therapy, chemotherapy immunotherapy and
gene therapy.27–31
In addition, several applications have been tested in fields other
than oncology, including MSK diseases and neurology (e.g. es-
sential tremor, neuropathic pain etc.).32
The learning curve of MSK MRgFUS users should be addressed
to (a) understand treatment effects and interaction between
ultrasound and different tissues, (b) develop strategies to reach
the target and the wanted effect and (c) build clinical, imaging
and technical selection criteria for patients.
(a) Not only bone but any tissue of the MSK system, as well
as nerves and vessels, may be targeted within certain limits
and purpose. The understanding of how organs with
different content in connective tissue absorb ultrasound is
critical, as well as the influence of tissue architecture on
ultrasound beam distortion. The concepts of skin and near/
far field “dose” (energy delivery) and strategies to reduce
risks of burns or loss of energy within the path should be
always taken into account. Correct shaving, preparation and
positioning of the patient are essential. Bowel interposition,
foreign material, large scars along the ultrasound beam path
should be avoided32 (Figure 3). Changes in the treated tissue
as well as in the surrounding background can significantly
alter the ultrasound effect in a “lesion-to-lesion” interaction
(occurring when the spatial separation of individual
exposures is such that an existing lesion seems to affect the
formation of a subsequent lesion).33 Cavitated areas may alter
the correct propagation of ultrasound. Background propagation
properties’ dependence on temperature has been demonstrated
through laboratory measurements of soft-tissue properties. For
typical FUS applications, only the slow variations in tissue
background parameters need to be accounted for when
computing the outcome of a FUS sonication. The cumulative
effect of slowly varying sound speed has been referred to in the
literature as a thermal lens, or a thermoacoustic lens because of
its beam-distorting properties.35,36
(b) From the pioneers of FUS, such as William Fyer, to modern
times, challenging organs were targeted, including moving
organs such as the liver and those needed for trans-skull
transmission.37,38 In more detail, new fascinating results have
been presented for intracranial applications, demonstrating
the possibility to produce focal intracranial thermal lesions or
temporary opening of the blood–brain barrier, for treating
movement disorders, and vascular, oncologic and psychiatric
diseases,39 from thalamotomy to gene delivery.32 With
specifically designed devices, MRgFUS can make the beam
pass through the cortical bone without loosing power and
energy and with no critical heating of superficial tissues and
bone. Transcranial MR-guided focused ultrasound has been
proposed for sonothrombolysis in the treatment of intracere-
bral haemorrhage and for acute stroke.40,41 Among other kinds
of tissues, liquids and not gas, help in the transmission and
should be considered as a “special tool” to make difficult cases
easier; in this regard, for instance, some authors reported their
experience in treating liver malignancies crossing the lung in
Figure 3. Axial view of a patient lying prone on the MRI-guided
focused ultrasound surgery table. The white arrow shows the
transducer (Figure 1), which can move in any direction to get
the most favourable acoustic window to the target. The
perfect preparation of media and positioning device (e.g. gel
pad, water bag etc.) in the near field are mandatory, in order
not to disturb the beam to the target, and to avoid or minimize
adverse effects (e.g. skin burns). In this case, the patient is on
a gel pad (broken arrows) with degassed water (arrowheads).
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the costophrenic angle by using intrapleural fluid infusion to
create an acoustic window for MRgFUS near the liver dome.42
Portable high-intensity FUS devices were tested for several
other applications in other tissues, including non-invasive
venous ablation,43 reduction of subcutaneous adipose tissue
and non-invasive body sculpting.44
(c) An analysis of factors affecting clinical success of MRgFUS
should be performed. The large experience on uterine
fibroids suggests the influence of several factors on ablation
[non-perfused volume (NPV)] and symptoms. NPV ratio,
which is highly correlated with clinical success, is significantly
higher in fibroids characterized by low signal intensity in
contrast-enhanced T1 weighted fat-saturated MR images and
lower in fibroids with septations, with subserosal component
and in skin-distant fibroids.45 An adequate patient and
strategy selection, combined with technical advances of the
system, may lead to higher clinical success and low compli-
cation rate. This kind of experience suggests the need, in
each field of MRgFUS application, of building clinical,
imaging and technical selection criteria for patients’ enrol-
ment. In this scenario, well-designed and comprehensive as
well as large studies are required on MRgFUS. Luo et al46
recently faced the problem and reported on for extracorpo-
real ultrasound-guided high-intensity focused ultrasound
(USgHIFU), on the basis of 75 controlled trials including
833 cases of benign and 4559 cases of malignant diseases.
FOCUSED ULTRASOUND, MRI AND
MUSCULOSKELETAL TISSUES: PROS AND CONS
MRgFUS has been approved for the treatment of painful bone
metastases in 2007 by CE and in 2012 by FDA, respectively.47–50
CE mark was later achieved for pain palliation, facet joint syn-
drome and benign bone tumours. In MRgFUS treatment, tissues
with the maximum acoustic absorption capacity are the most
desirable targets; in the MSK system, these are the cortical bone
and high-density fibrous tissues.
Therefore, sonication power used for bone applications is typically
low, making the treatment even more safe for surrounding tissues.
Furthermore, spot size can be large since the focus can be placed
beyond the cortical bone to exploit the heating distribution along
the cortical surface (fewer sonications needed). However, sur-
rounding tissues, including tendons, ligaments, vessels and nerves
are heated by the heated bone, and the bone may also produce
partial reflection in wanted or unwanted directions and this should
be taken into consideration; with commercially available systems,
cortical and trabecular bone is difficult to be crossed.
Superficial structures are at risk of skin burns; deeper structures
are burdened by the different layers to be crossed from the
beam. The focus can shift away from the desired point because
of tissue inhomogeneity. The correction of distortions induced
on the ultrasound beam during its propagation through defo-
cusing obstacles is challenging and several improvements oc-
curred in sonication parameters.51
Few layers of homogeneous tissues in terms of density, archi-
tecture and orientation are desirable for the optimal beam path
to get the desired effect and to avoid dispersion of energy or
dangerous deviation.52 The reflection and absorbing properties
of the near field and target tissue should be considered (calci-
fications, scars etc.), as well as the distance of critical structures
from heated tissues (skin, nerves, which are plunged in con-
nective tissue). Nonetheless, the far field should be considered in
light of the expected delivery of energy on the target: with bone
as target the far field is protected by the low-energy sonication to
be used and by the high absorption/reflection of bone; with
a soft-tissue target, a higher energy sonication must be used and
the beam will impact the far field still with a significant energy
load. For instance, the effects of fascia lata on HIFU-induced
lesions were demonstrated through comparison with and
without fascia lata in bovine thigh muscle tissue; fascia lata was
confirmed to contribute in increasing tissue necrosis, tempera-
ture elevation and echogenicity in ultrasound images.53
On the other side, the most important advancements in MRI-
guiding HIFU (MRgHIFU) were on intraprocedural monitoring
of treatment effects, therefore on MR thermometry.54,55 The goal
of MRI-guided thermal therapy is to better control the treatment
outcome by using real-time temperature mapping. In this regard,
the temperature needs to be accurately measured during the
treatment, but also to be related to thermal tissue damage.
Non-invasive temperature monitoring is feasible with MRI;
several temperature-sensitive MR parameters are involved, such
as T1 and T2 relaxation times, proton resonance frequency (PRF),
diffusion coefficient, proton density, magnetization transfer and
temperature-sensitive contrast agents. The most affirmed method
to drive HIFU was based on PRF shift method. The temperature
sensitivity of PRF was first observed by Hindman56 in 1966, and
implemented for spectroscopy; later it was adapted for MRI-
temperature monitoring by Ishihara et al57 and De Poorter
et al.58 Two techniques have been developed from temperature
imaging based on the PRF shift: spectroscopic imaging and
phase-mapping method. MRI-derived temperature maps can be
realized by using gradient-recalled echo imaging sequences; more
in detail, phase changes (resulting from temperature-dependent
changes in resonance frequency) are measured. PRF thermal
coefficient is basically tissue type independent (except for adipose
tissue); even when tissues have been coagulated, only a small
influence has been observed. Indeed, this independence of the
PRF shift from tissue type is true only for aqueous tissues. In
water, the relationship between PRF and temperature is mainly
based on changes in the hydrogen bonds, absent in adipose tis-
sue; therefore, susceptibility effects are almost completely re-
sponsible for the temperature dependence of PRF in fat. The
resulting sensitivity on temperature of fat is very small, making
thermometry in fatty tissue difficult. The described difference in
thermometry in aqueous and fatty tissues represents a challeng-
ing issue for temperature measurements by using PRF, since water
and fat coexist in many biological tissues. PRF-thermometry is
limited to water-based tissues and temperature is not measured
in the bone and marrow, as well as in the adipose tissue. Because
information on temperature within the bone is not provided by
the existing techniques of MR thermometry, these are moni-
tored by measuring temperature changes in the surrounding soft
tissues.56–58
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Efforts were directed to improve the accuracy of volumetric MR
thermometry and in finding reliable methods to correlate the
temperature in high-lipid tissues and in the bone. A model-based
correction procedure for PRF shift thermometry errors caused by
heat-induced magnetic susceptibility changes during HIFU ab-
lation in tissues containing fat (breast fatty samples) was pro-
posed by Baron et al.59 A non-parametric temperature controller
with non-linear negative reaction for multipoint rapid MRgFUS
was proposed by Petrusca et al.60 Experimental methods for
improved spatial control of thermal lesions in MRgHIFU abla-
tion were also proposed.61 Available and accurate methods for
retrospective reconstruction of the temperature maps useful in
research settings were investigated.62,63 A recent study by Ramsay
et al64 proposes to monitor temperature changes in the cortical
bone using a short echo-time gradient echo sequence. The fea-
sibility of using T2 mapping to monitor the temperature change
in subcutaneous adipose tissue layers was studied by Baron
et al.59,65 Temperature monitoring and hyperthermic injury de-
tection in fatty tissue was also tested by using X-ray CT during
HIFU thermal treatment.66 Diakite et al67 recently presented
a three-dimensional segmented echoplanar imaging pulse se-
quence implementation that simultaneously provides the proton
resonance frequency shift temperature of aqueous tissue and the
longitudinal relaxation time (T1) of fat during thermal ablation.
Another study evaluated the accuracy and precision of two non-
invasive thermal diffusivity estimation methods,68 and MR
acoustic radiation force imaging, in order to propose an elegant
adjunct to MRgFUS for treatment planning and optimization,
permitting in situ assessment of the focusing and targeting
quality.69 Even real-time methods are being developed for
motion-compensated MRI thermometry in MRgHIFU treat-
ment of abdominal organs, which may be considered in the
treatment of the chest wall.70
The development of reliable and accurate MRI methods was also
devoted to post-treatment imaging. A recent study by Fite et al71
compared in mice the correlation between histological findings
and common MRI protocols in the assessment of the extent of
thermal damage. This research found a good correlation between
non-enhancement area on contrast enhanced T1 weighted imag-
ing immediately after ablation and the region of tissue receiving
a thermal dose. Moreover, although both tumour T2 and apparent
diffusion coefficient values changed from pre-ablation values,
contrast enhanced T1 weighted images appeared to be more
sensitive to changes in tissue viability following HIFU ablation.71
Other imaging options may help to better understand and in-
vestigate the connectivity of nerves and other functional struc-
tures (e.g. diffusion-tensor MRI).71
MRGFUS TARGET AND APPLICATIONS IN
MUSCULOSKELETAL PATHOLOGY
Oncology
Both benign and malignant, primary and secondary, bone
tumours are the target of imaging-guided interventions. How-
ever, owing to the curative intent, and to good surgical and
medical outcome of today’s clinical practice, imaging-guided
procedures are not considered as first-line treatment options for
primary malignant bone or soft-tissue tumours. These are more
advocated for benign tumours or for palliation in primary and
overall secondary malignant bone tumours.73
Fire and ice: thermoablation is definitely the most realized effect
of interventional imaging-guided procedures in the treatment of
benign and malignant MSK tumoral lesions. Several techniques
are used to determine this effect such as continuous radio-
frequency, laser, microwaves and cryoablation. Different tech-
niques have been associated with different imaging methods,
with advantages and disadvantages, with a certain comfort of the
patient; of course, each technique has shown a certain effec-
tiveness in several clinical settings. Different combinations in-
fluence the choice, development and optimization of treatment
management in different clinical scenarios and disorders (lesion,
patient and aim features, site etc.). However, techniques such as
radiofrequency ablation are usually still CT imaging guided and
require at least a percutaneous approach.74
A recent article reviewed the clinical applications of FUS and
provided a comprehensive overview of HIFU employment on
bone tumours, describing background, results of clinical studies
and suggesting future directions.75 MRgFUS has been first
proposed with a potential in pain palliation of bone metastases,
for its good results in patients non-responding to radiotherapy
while applying acoustic energy on the bone surface resulting
in bone cortex heating, and indirectly ablating the adjacent
periosteum—the most innervated component of mature bone
tissue, and tumour tissue, and a major source of pain.11,76 The
bone is a common site for metastasis. The primary cancers that
most frequently metastasize to bone are breast and prostate
cancers (post-mortem incidence of bone metastases: breast 73%,
prostate 68%, thyroid 42%, lung 36%, renal 35%), and these are
among the most incident and curable worldwide. The treatment
of painful bone metastases is of primary importance in terms of
both the quality of life of the patient and economy, and this
should be considered in light of the increasing survival of
patients with cancers. Bone metastases are the most common
cause of cancer-related pain.77 The development of strategies to
improve the quality of life in patients with bone metastasis is
fundamental and represents a major clinical challenge. In this
scenario, MRgFUS can work with the aim to produce fast and
long-lasting pain relief while providing several advantages: no
ionizing radiation, lack of cumulative dose, several lesions might
be treated per session, treatment might be repeated as many
times as needed, fast pain relief, contraindications limited to
those of the imaging guide (MRI) and general fitness to anaes-
thesiological choices.78–80
Among several experience, preliminary prospective cohort
studies on using MRgFUS for painful bone metastases (in
patients for whom other treatments were either ineffective or
not feasible) were published between 2007 and 2009, with sat-
isfying effects in terms of pain palliation. The first multicentre
study on this topic was published by Liberman et al,81 including
previous pioneering works from Catane et al82 and Gianfelice
et al.83 The study by Liberman et al81 comprised 31 patients
(32 bone lesions), and lead to CE mark of conformity of
MRgFUS for the role of palliation in painful bone metastases.
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A 3-month follow-up was available for 25 patients. The average
visual analogue scale (VAS) score decreased from 5.9 to 1.8 at
the 3-month follow-up with 18 (72%) patients experiencing
a significant reduction in pain and 9 (36%) with the VAS score
dropped to 0; 52% of patients reported substantial pain relief
within 3 days, 24% had no response and one patient (4%) ex-
perienced worsened pain levels. A reduction in opioid usage was
registered in 67% of patients. No major complications were
reported.81 Napoli et al10 presented a single-centre experience
with 18 patients and found increased bone density with resto-
ration of cortical borders in 5 of the 18 patients treated with
MRgFUS (27.7%) (the overall pain response rate was 89% with
complete pain relief in 72% of patients). According to MD
Anderson criteria, complete and partial responses to treatment
were observed in two (11.1%) and four (22.2%) cases, re-
spectively, and the NPV values ranged between 20% and 93%,
with mean NPV values substantially stable after the treatment.10
This represented the first concrete experience which actual ex-
tended the potential role of MRgFUS even to the hypothesis of
local tumour control (Figures 2 and 4). Hurwitz et al recently
published the results of the first Phase III trial supporting FDA
approval in the USA, giving a new substantial contribution to
the evidence of safety and efficacy of MRgFUS in the palliation
of painful bone metastasis. In this study, 147 patients affected by
painful bone metastases were randomly assigned to MRgFUS
sonication or placebo group (3 : 1). The primary end point was
represented by an improvement in self-reported pain score
without pain medication increase during the 3 months after
treatment (at least two-point decrease in the Numerical Rating
Scale for pain score and equivalent daily dose intake of mor-
phine not increasing by.25% when compared with the baseline
dose). Response rate was 64.3% in the MRgFUS group and
20.0% in the placebo group (p, 0.001). MRgFUS was superior
to placebo at 3 months [worst Numerical Rating Scale for pain
score and the brief pain inventory-quality of life (p, 0.001)].
The most frequent adverse event was sonication pain, occurring
in 32.1% of patients with MRgFUS. Pathological fractures were
reported in two patients, third-degree skin burn and neuropathy
were reported in one patient each; overall, 60.3% of the adverse
effects were resolved within the same day of the treatment. This
study demonstrated that MRgFUS is a non-invasive and safe
treatment in painful bone metastases for patients in whom
standard treatments have failed.11 Recently, an article published
by an international consensus held at the Focused Ultrasound
Therapy Second European Symposium in Rome (2013), Italy,
focused on the point about current treatment goals, current
indications, technical considerations, future directions including
research priorities, and economic and logistical considerations.84
A systematic literature review of image-guided FUS and bone
metastases was performed, scanning between 1980 and June
2014. An overview of all clinical studies and abstract results on
image-guided FUS for painful bone metastases was presented.
Preliminary clinical studies concluded that MRgFUS offers
a potentially safe and effective non-invasive treatment option
for radiation refractory metastatic bone pain, with .70% of
patients experiencing pain reduction after MRgFUS treatment.
The biological mechanism of pain relief induced by FUS treat-
ment has not been completely elucidated, although it is generally
assumed, as previously mentioned, that periosteal denervation
induced by cortical heating plays a major role with duration of
pain relief of at least 3 months. More aggressive ablations may
lead to local tumour control and improve pain relief but may
also generate more adverse events. In patients with advanced
disease and limited survival (6 months), local tumour control
should not be pursued since the potential additional risks of
more aggressive treatment strategies do not outweigh the ben-
efits for these patients.84
Important benefits of FUS compared with radiotherapy are (a)
the absence of ionizing radiation, (b) the ability to induce pain
relief within 3 days of treatment, whereas radiotherapy may have
a delay in response of up to 4 weeks, (c) the higher response
rate, longer response duration if compared with re-irradiation,
(d) fewer side effects, (e) no need to interrupt chemotherapy for
FUS, (f) generally only a single session is needed, although re-
peat exposures are possible. Disadvantages of FUS include (a)
the common need for anaesthesia and (b) for patients to be able
to undergo MRI for MRgFUS, and (c) potential positioning
problems, to get full access and window to the target area
(possible solutions with MRgFUS conformal bone system or
Figure 4. Bone metastasis from breast cancer before (a) and 3 months after (b) MRI-guided focused ultrasound surgery at fluorine-
18 fludeoxyglucose positron emission tomography/CT imaging. SUV, standardized uptake value.
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USgFUS). Moreover, FUS is currently not suitable for skull
metastases or spinal metastases (except for the posterior ele-
ments, in safe conditions e.g. below the level of the conus
medullaris). Spinal metastases cannot be faced at the moment
because of concerns about thermal damage to the spinal cord,
and for technical and accessibility challenges.85 Since approxi-
mately one-third of patients with painful bone metastases have
lesions in the thoracic or lumbar spine, efforts on significant
engineering development are being directed to accomplish this
goal. It has been anticipated that in the future, it will be tech-
nically possible to treat metastases in the entire vertebral
column.85
Consensus has been reached that FUS is an acceptable sec-
ondary treatment option for patients who have painful bone
metastases in a non-spinal site, for whom radiotherapy has not
been effective. FUS can be considered as a primary palliative
treatment option in patients for whom radiotherapy may be
contraindicated (e.g. prior radiation) or has been refused. Fu-
ture directions and research purpose include the local tumour
control and the role as primary treatment, the potential in-
tegration of FUS in a multimodality setting treatment of spinal
metastasis, and the design of registry and randomized clinical
trials. Selection criteria and understanding of specific biological
response of different cancers to FUS thermoablation should be
also investigated. Currently, a randomized controlled trial of
MRgFUS vs radiotherapy for the primary palliative treatment of
metastatic bone pain is open to accrual in Europe (trial registry
no. NCT01091883).
Today, palliative treatment of bone metastases is still the only
application in oncology and musculoskeletal pathology for which
FUS has received approval in the USA.
Traditionally, MRgHIFU treatments consist of multiple single
focal point sonications, referred to as point-by-point ablation. In
2011, a different MRgFUS system with volumetric ablation
capabilities was CE marked for the treatment of painful bone
metastases. 11 patients underwent 13 treatments for 12 bone
metastases. No major adverse events were observed during or
after the procedure. At 3 days after the ablation, significant
decrease in pain scores was observed in 6 of 11 (55%) patients.
At 1-month follow-up (available for nine patients), a significant
decrease in pain scores was observed with six of nine patients
obtaining pain response (overall response rate 67%; 95% con-
fidence interval 35–88%).86 A bone-dedicated transducer (con-
formal bone system) has been developed and is currently
approved by CE mark. This is a mobile multielement (1000
elements) transducer with no mechanical but electronic steering
which is directly applied to the skin surface to be used as
acoustic window to access the bone lesion. The frequency is
fixed to 0.55MHz, and the transducer is provided with a water-
permeable membrane to provide acoustic coupling and in-
tegrated built-in skin cooling system. The experience in using
this kind of transducer is still limited87 (Figure 5).
Experience in the treatment of primary malignant bone tumours
comes from Chinese researchers and authors and is limited to
USgHIFU. The first FUS bone treatment was performed in
China, for a tibial osteosarcoma in December 1997. Several
articles presented series of patients treated mainly for limb sal-
vage or with FUS with palliative intent, in combination or not
with chemotherapy.88–91 In 2010, Chen et al92 reported long-
term follow-up results of a non-randomized clinical trial of
USgFUS for the treatment of 80 primary malignant tumours
(60 Stage IIb and 20 Stage IIIb patients according to Enneking
staging). 62 patients affected by osteosarcoma, 1 with periosteal
osteosarcoma and 3 with Ewing’s sarcoma underwent FUS
combined with chemotherapy. The remaining 14 patients with
chondrosarcoma, malignant giant-cell tumour of the bone,
sarcoma of the periosteum or with unknown histology received
FUS alone. Complete ablation of the tumour was observed at
follow-up images, whereas ablation covering .50% of the tu-
mour tissue was seen in the remaining 11 patients. The overall
5-year survival rate was 51%, with 64% and 16% for patients
with Stage IIb and III disease, respectively. Only 5 out of the
69 patients who underwent complete ablation had local cancer
recurrence during the follow-up period (5–87 months). All
patients experienced mild pain and, among other adverse events,
28% were major complications; in this group, 11 patients re-
quired surgery and 8 presented severe peripheral nerve damage.
In these last cases, the distance between the damaged nerves and
the tumour margin was ,10mm, suggesting that 10mm is
a reasonable safety margin to avoid nerve damage in FUS
treatments. Although several articles were published about this
topic, there is only limited evidence to consider the technique
suitable for this application. Much stronger evidence and trials
might allow HIFU to enter a limb-salvage treatment approach or
to be considered for neoadjuvant–adjuvant therapy in primary
bone tumours. An editorial by Konski commented on the study
by Li et al;90 HIFU may provide another treatment option for
patients with primary bone tumours who are not surgical can-
didates or who refuse surgery, but these data need to be con-
firmed. A reply by Bielack et al93 suggested that experimental
approaches should not be considered “safe” unless they are
proven to produce equivalent local control rates, and we think
that this opinion should be shared and supported.
Italian researchers were mainly involved in testing MRgFUS for
the treatment of benign bone tumour, especially osteoid oste-
oma, with excellent results in terms of efficacy and safety;94,95 in
particular, one recent prospective multicentre study95 including
30 consecutive patients with non-spinal osteoid osteoma re-
ported a complete clinical success rate of 90% without adverse
events.94,95 Anecdotal experiences have been reported for other
epiphyseal benign bone lesions (e.g. periosteal chondroma).
However, this topic will be specifically addressed by other
authors in this special issue (Figure 6).
Standardization of validated assessment instruments facilitates
comparisons of clinical studies and should be pursued. Taking
into account overall response inclusive of complete and partial
responses as a baseline for comparisons, the responder group
varied within 92–100%, 85–87% and 64–87% for primary be-
nign, primary malignant and metastatic tumours, respectively.
In treatments with a curative aim, the recurrence rate was
0–14%, and in palliative treatments, the pain progression was
0–13%. A comprehensive review of results demonstrates the
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efficacy of FUS for both palliative and curative purposes in the
treatment of bone tumours. Major complications were reported
in the ranges of 0%, 0–28% and 0–4% for primary benign,
malignant and metastatic tumours, respectively.75
Degenerative diseases
Osteoarthritis (OA) is a common, disabling and costly disease.
The predominant symptom is pain. Effective non-invasive
treatment approaches are missing. The vast majority of joint
replacement surgery procedures are performed because of pain.
The need for new therapeutic options is even enhanced by the
ageing of the population, responsible for the increasing symp-
tomatic population affected by OA. The management of OA is
still a matter of debate.96,97 OA disease is heterogeneous and
characterized by failure of the synovial joint organ. The deter-
minants of pain in OA are not well understood but are believed
to involve multiple interactive pathways, and inflammatory
mediators contributing to sensitize nociceptors. An important
component of the biological contribution to pain comes from
the multitude of tissues containing nociceptive fibres within the
Figure 5. Conformal bone system. A transducer dedicated to bone applications was developed and is currently European
Conformity (CE) approved. (a) This is a mobile multielement (1000-elements, 0.55-MHz) transducer with electronic steering which
can be directly applied to the skin surface to be used as acoustic window to access the bone lesion and to improve the comfort of
the patient. In (b) the transducer is applied for the treatment of a metastasis to the humerus from prostate cancer, with the patient
lying supine; T2 weighted images with fat saturation show a slight oedema of the surrounding soft tissue after treatment.
Figure 6. Osteoid osteoma of the femur [CT image, (a)] treated by MRI-guided focused ultrasound surgery, with perfusion imaging
before (b) and after (c) the treatment showing the nidus blowing out (arrows).
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joint; the subchondral bone, periosteum, periarticular ligaments,
periarticular muscle and joint capsule including its inner syno-
vial lining are all richly innervated and are the likely source of
nociception in OA.98 The cartilage is in the “spotlight” in the
field of OA; nonetheless, it is important to note that this disease
of the whole joint concurrently affects other tissues that do
contain nociceptors. A recent study suggested that areas of de-
nuded cartilage are related to symptoms. Other bone-related
causes of pain include periostitis associated with osteophyte
formation, subchondral microfractures, bone attrition and bone
angina due to decreased blood flow and elevated intraosseous
pressure, resulting in bone marrow lesions at imaging. Synovial
causes of pain also include irritation of sensory nerve endings
within the synovium from osteophytes and synovial in-
flammation. The National Institute for Health and Care Excel-
lence suggests to consider referral for joint surgery for people
with OA who experience joint symptoms (pain, stiffness and
reduced function) with substantial impact on their quality of life
and refractory to non-surgical treatment.97
MRgFUS has been recently applied for the treatment of pain
related to facet joint syndrome and to knee OA by two different
research groups. Their preliminary experiences have been de-
scribed in two pilot studies, demonstrating the safety of the
procedure and the potential efficacy while achieving satisfying
results in terms of pain relief. The treatments were performed by
using both “conventional” and “conformal” bone systems.99,100
Low back pain is a leading cause of activity limitation and work
absence throughout the world, imposing a high economic bur-
den on individuals, families, industry and governments.101 Facet
joint pain represents a consistent part of low back pain, and its
treatment and management are subjects of great controversy.
Several methodological limitations have led to poor evidence
and non-widely approved conclusions for current treatment
options. Facet joints have a rich innervation arising from the
medial and lateral branches of the dorsal rami with dual in-
nervation from the medial branches arising from the posterior
rami. In most cases, the treatment strategy is still unsatisfactory.
MRgFUS received CE mark for facet joint syndrome in June
2013, after a preliminary experience, with great potential, of
Weeks et al99 who published in 2012 the first reliable clinical
application of MRgFUS for OA, specifically for facet joint syn-
drome (Figure 7). In a Phase I observational pilot study, the
authors enrolled 18 patients with a positive response to facet
joint interventions. MRgFUS was performed at the levels of pain
according to symptomatology, previous invasive treatment and
MRI grading of facet joint OA, and evaluated pain, function and
quality of life. At 6 and 12 months, they found a reduction in
both average and worst numerical rating scale pain scores of
about 60.2%/51.2%, with of 45.9% in Oswestry disability
questionnaire score and 61.9% reduction in the brief pain in-
ventory interference score. According to EuroQol, they observed
an improvement in the health state score based on UK coef-
ficients of 10.379 (0.317–0.696). No major adverse events were
observed. They demonstrated, in such a difficult clinical entity,
that MRgFUS is safe, free of complications, effective and well
tolerated, after a rigorous diagnosis including diagnostic blocks,
which are the best approach to select patients for treatment,
since no physical examination findings are pathognomonic for
diagnosis.99 Summary of pre-clinical phase for facet joint
treatment was published by Harnof et al.102
The risk of mobility disability attributable to knee OA alone,
affecting general well-being and performance at work, is greater
than that due to any other medical condition in people aged
65 years and over. A study by Izumi et al100 opened the appli-
cation of MRgFUS to other important joints, such as the knee.
Although there is still not a marking of conformity or approval
about the use of FUS in knee OA, this study showed the safety
and potential efficacy of MRgFUS in eight patients with medial
knee pain, eligible for total knee arthroplasty. The pain intensity
during walking was assessed by VAS before and after treatment,
and pressure pain thresholds were also evaluated in the sonica-
tion area and in control sites 1 month after treatment. Six
patients (75%) showed immediate pain alleviation after treatment,
Figure 7. MRI-guided focused ultrasound surgery (MRgFUS) treatment for facet joint syndrome. Osteoarthritis with facet joint
involvement is shown in (a) (broken arrows). A screenshot of the MRgFUS procedure shows facet joints targeted on the MR
planning image (b), and a thermal map image (c) caught during sonication highlights the thermal effect reached on the target
(ablation/denervation) (courtesy of Dr Mattia Squarcia, Hospital Clinic-Centre Me`dic Alomar Barcelona, Spain).
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and four of them demonstrated long-lasting effect at 6-month
follow-up (mean VAS reduction; 72.6%), with pressure pain
thresholds significantly increased after treatment in responders.
No adverse side effects or complications were observed.100
The above mentioned studies open to a new field, with poten-
tially very huge impact, both in terms of new options in treating
pain from the most prevalent joint disorders, OA, as well as in
new insights into joint function pathophysiology.
Miscellaneous and soft-tissue lesions
Very few articles propose HIFU for MSK soft-tissue ablation.
All major studies use USgHIFU. An experience by Wang et al103
showed the potential of using HIFU in treating extra-abdominal
desmoid tumours. Ten patients with pathologically proven
extra-abdominal desmoid tumours were submitted to USgHIFU
ablation. Curative aim was possible in two patients with new
solitary tumours, whereas the procedure was performed with
palliative aim in eight patients with multiple, recurrent tumours.
The mean size of the largest tumour was 9.2 cm (range
5.9–12.8 cm). Large areas of coagulation necrosis were obtained
in all patients. 25 treated tumours significantly shrank in vol-
ume (.50%) during a mean follow-up of 30 months (range
8–55 months); in 2 patients with solitary tumours, complete
tumour necrosis was observed. HIFU was repeated in two
patients for growing residual tumours. No major complications
were observed.
In a series of patients with solid malignancies, Orgera et al104
evaluated the feasibility, local tumour response and clinical
results of USgHIFU. Among these, soft-tissue metastases from
colorectal carcinoma and muscle metastasis from lung, and one
abdominal liposarcoma were presented. All bone and soft-
tissue were described palliated in symptoms, with complete
response to positron emission tomography (PET)/CT, multi-
detector CT or MRI; the liposarcoma was almost completely
ablated at MRI.104
Local control of primary synovial spindle cell sarcoma of the
chest wall was attempted by Hu et al.105 After four cycles of
chemotherapy, local recurrence of the sarcoma was detected.
Subsequent extended resection confirmed synovial sarcoma.
After five cycles of a new chemotherapy option, the sarcoma
relapsed again. The patient subsequently received five courses of
HIFU; this was described to completely ablate the sarcoma
without complications.105
Other experiences also involving MRgFUS in the treatment of
aggressive fibromatosis, haemangiomas (with particular fea-
tures), as well as other soft-tissue masses have been presented in
abstracts and conferences as anecdotal and must be confirmed
by more extensive research.106
From pre-clinical evidence to practice
A number of studies investigated the effects of ultrasound on
biological tissues. The best known method of HIFU is thermal
ablation, but interest in non-thermal, mechanical destruction is
increasing. The advantages of mechanical ablation are that
thermal protein denaturation remains limited, and less damage
is created to the surrounding tissue by thermal diffusion.107
During HIFU applications, tissue necrosis may be obtained by
heating, or the tissue can be emulsified by cavitation; as recently
reported, the tissue can also be emulsified by using repetitive
millisecond boiling (caused by shock wave heating).108 During
treatment, ultrasound reflections from distal media interfaces
can shift prescribed treatment locations. By targeting the focus
“behind” the bone, the same result can be achieved with a single
sonication only. MRgFUS by both energy deposition methods
can be used to produce controlled well-localized damage to soft
tissue in close proximity to the bone, with minimal collateral
damage.109 Comparing the effect of normal incidence reflections
from air, acrylic (modelling bone) and rubber on treatment
location, temperature elevation and heating patterns by per-
forming ultrasound exposures, results demonstrated a shift in
treatment location towards the distal interface when targeted
closer than 2 cm from the interface, especially for acrylic: ul-
trasound wave reflections from a distal air interface had less
effect than the acrylic interface (modelling bone) on the heating
pattern and focal location.110
“Paleoresearch” of interactions between MSK tissues and HIFU
were published.111–113
Thermal effects due to high ultrasound absorption in bone pose
an ongoing safety issue regarding the heating of the soft tissue
adjacent to the bone surface. Mathematical models have been
developed to predict the temperature rise at bone/soft-tissue
interface.114 The comprehension of effects on bony structure and
function after HIFU is of crucial importance. Several experiences
on bone remodelling processes induced by thermo-related
coagulative necrosis were also reported. Bucknor et al115 in-
vestigated hyperacute (,1 h) changes following MRgFUS at MR
and CT in relation to sonication number and energy in a swine
bone model; increasing the sonications’ number from four to six
caused a significant increase in the depth of the intramedullary
hypoenhanced zone (from 2.9 to 6.5mm; p, 0.001) within
similar volumes. No significant difference was observed between
low- and high-energy ablations. CT images did not reveal
structural abnormalities. This study concluded that the number
of sonications can be used to increase the treatment depth within
the target in the bone. T2 weighted and contrast-enhanced MR,
and not CT, can show the hyperacute structural changes of the
bone and surrounding tissues.115
Recently, Bucknor et al also provided additional information
by studying bone remodelling in the swine femur after
MRgHIFU ablation with MRI, CT, Na(18)F-PET and histo-
pathological examination, as a function of sonication energy.
Eight pigs were evaluated before and 3 and 6 weeks after
MRgHIFU with 3-T MRI and 64-section CT [4 pigs were also
evaluated using (18)f-sodium fluoride-PET (Na(18)F-PET)
and histopathological examination]. Ablation sizes at MRI 3
and 6 weeks after MRgFUS were similar between proximal
(low-energy) and distal (high-energy) lesions, although distal
ablation lesions demonstrated evidence of subperiosteal new
bone formation at CT, with a subtle focus of new ossifica-
tion at 3 weeks and a larger focus of ossification at 6 weeks.
New bone formation was associated with increased uptake at
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Na(18)F-PET in three of four animals undergoing PET; this
was confirmed at histopathological examination in all four
animals. MRgHIFU ablation of bone may result in progressive
remodelling, with both subcortical necrosis and subperiosteal
new bone formation. This may be related to the use of high
energies. MRI, CT and PET are suitable non-invasive techniques
to monitor bone remodelling after MRgHIFU ablation.116
Another interesting study was conducted by Herman et al117 in
2013. This author investigated biomechanical properties of the
bone treated by MRgHIFU in four minipigs. The treatment was
performed in six consecutive right normal ribs, whereas the
corresponding left ribs were used as controls. A reduction in
bone biomechanical properties was observed 6 weeks after
treatment in the treated ribs, with a mean6 standard deviation
yield load ratio and maximum ratios of 0.696 0.11 and 0.716
0.13, respectively (both p5 0.031). Some recovery trend was
observed at 12 weeks after treatment. Significant reduction in
mean osteon size was reported at histological analysis at 2 weeks
after treatment in control vs treated bones, respectively
(p5 0.005). An approximate 30% reduction in mechanical
strength was observed in the treated bones at 6 weeks post-
treatment, with a reversible trend at 12 weeks post-treatment
(reduced from 30% to 25–20%).117
Safety guidelines are required for treating tissue masses on or
near the bone by using MRgFUS,118 since the presence of bone
would directionally change the spatial distribution of acoustic
pressure, and thermal and cavitation effects for oblique in-
cidence of HIFU.119 In addition, HIFU may be generated as
pulsed or continuous depending on the device and medical
purpose. HIFU treatments on muscle tissue induce severe
changes in gene expression; however, continuous or pulsed
HIFU cause the upregulation of the same genes, meaning that
the tissue reaction is not influenced by the type of damage.120
Effects of ultrasound were studied also on other tissues and
components of the MSK system, such as muscles, tendons,
ligaments, and synovial, meniscal and discal tissues, as well as
on nerves and vessels.121–124
HIFU beam was tested on bovine tendons ex vivo, highlighting
the potential of HIFU as a non-invasive treatment option for
chronic tendinosis.125 Foldes et al126 proposed to study the fea-
sibility of MRgFUS to non-invasively perform synovectomy in
rabbit knees, with partial synovectomy resulting in five animals.
Studies evaluated probes as an alternative technology for
meniscal debridement in the bovine knee,127 and for collagen
shrinkage in intervertebral disc.128,129 A number of studies
reported the therapeutic potential of low-intensity pulsed ultra-
sound in the induction of bone repair,130 as well as in avoiding
the development of disuse muscle atrophy partly via activation of
satellite cells.131
The effects of focused and unfocused ultrasound on nerves,
vessels and adipocytes also deserve special consideration both for
therapeutic implications and for safety issues.131 Studies on
functional effects and of the potential disruptive effects of FUS
on nerves date back to the mid-20th century. FUS of the whole
nerve produces differential conduction blocking of mammalian
nerve fibres. The smallest (C) fibres are more sensitive, whereas
the largest (A-alpha) are less vulnerable. Complete reversible
blocking can be reached through graded doses of ultrasound.133,134
Single pulses of FUS have been observed to significantly
modify neuronal excitability in vitro. Pulsed FUS can stimulate
the receptor and conductive nerve structures of humans and
animals as well as the neurons of the central nervous system of
invertebrates.135 Colucci et al136 more recently studied the
application of FUS on sciatic nerves in bullfrogs. The nerve
action potential was shown to decrease in the experiments and
correlated with temperature elevation measured in the nerve.
The action potential recovered either completely, partially or
not at all, depending on the parameters of the ultrasound
exposure. These results indicate that a thermal mechanism of
FUS can be used to block nerve conduction, either tempo-
rarily or permanently.136 Foley et al137 investigated the effects
of various exposures (intensity, duration) of HIFU on sciatic
nerve conduction in rats, with the aim to identify HIFU
exposures that produce biological effects ranging from partial
to complete conduction block, indicating potential use of
HIFU as an alternative to current clinical methods of inducing
nerve conduction block.137 HIFU was demonstrated to at-
tenuate neural responses of sciatic nerves isolated from nor-
mal or neuropathic rats, with diabetic nerves being less
suppressed by HIFU and more vulnerable to permanent
damage.138 Neurolysis, blocks, neuromodulation are possible
applications of FUS.139,140
Among studies on vascular applications, Ishikawa et al141
demonstrated how, in rats, the response of the artery to HIFU
varied with intensity. Vascular contraction without tissue de-
generation occurred at low intensity; by increasing the intensity,
the tissue degeneration was detectable in histology and the
vascular diameter was reduced, and finally, at high intensity, the
blood flow was occluded. Although these phenomena appeared
to be mainly due to thermal effects, mechanical effects might
have some role, particularly on vascular contraction. HIFU was
also investigated for sympathetic denervation.141
A study was aimed at detecting changes in the cell membrane
of Sarcoma 180 (S180) cells induced by FUS and to probe the
underlying mechanism. The results revealed that the instant
cell damage effects induced by ultrasound might be related to
the improved membrane lipid peroxidation levels post-
treatment. The physicochemical properties of S180 cell mem-
brane were changed by FUS. The findings also implied an
exposure time-dependent pattern and suggested that the lipid
peroxidation produced by acoustic cavitation might play im-
portant roles in these actions.142 The histological changes,
including the antitumour immunological response, after HIFU
treatment were examined in soft-tissue sarcoma. HIFU, even
when administered as a single shot, induces apoptosis of tu-
mour cells and intratumoral infiltration of macrophages and
lymphocytes.143
Non-surgical opportunities
Thermal therapy can be performed in two regimes. The first one
is high-temperature ablation, with temperatures in the range of
50–80 °C (or higher) applied for a short time interval to rapidly
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induce coagulation necrosis through processes such as protein
denaturation. The second is low-temperature ablation, with
temperatures in the range of 43–45 °C applied for a longer time
interval (tens of minutes) to directly induce cancer cells’ death
or to make them more sensitive to cytotoxic agents and/or
radiation.144–153
Staruch et al154 studied control strategies and drug delivery with
temperature-sensitive liposome hyperthermia in bone, generated
with MRgFUS. Significant increases in doxorubicin concentra-
tion occurred in heated vs unheated marrow (8.2-fold) and
muscle (16.8-fold). Enhancement occurred for 0- and 10-mm
offsets, suggesting that localized drug delivery in bone is pos-
sible with both hyperthermia and thermal ablation. Thus, this
demonstrated that MRgFUS can achieve localized hyperther-
mia in bone for image-guided drug delivery in the bone with
temperature-sensitive drug carriers.154
Potential mechanism inducing apoptosis in sonodynamic ther-
apy and FUS were investigated in S180 cells in vitro;155 in par-
ticular, how pulsed HIFU-mediated nanoparticle delivery in
murine muscle.156
Current commercially available MRgFUS devices are marketed
for their thermal ablation applications. In the future, lower
energy treatments may play a significant role in mediating tar-
geted drug and gene delivery for cancer treatment.27
SAFETY
HIFU treatments are usually carried out in a single session, often
as a day case procedure, with the patient either fully conscious,
lightly sedated or under locoregional or general anaesthesia.
Errors in the preparation of patient and in positioning should
be accurately ruled out. Small scars can be avoided by placing
appropriate sticks and with a good planning of the procedure.
In the Phase III trial for treatment of skeletal metastasis, the
most common treatment-related adverse events were sonica-
tion pain (32.1% of patients) for insufficient anaesthesia,
followed by pathological fractures (two patients) for in-
sufficient anaesthesia, severe skin burn and neuropathy (one
patient each). Around 60% of the adverse effects resolved on
the same day of the procedure.11
In the study of treatment of primary malignant bone tumours
with USgHIFU by Chen et al, all patients experienced mild pain,
and among other adverse events, 28% were major complications
where 11 of these patients required surgery and 8 presented se-
vere peripheral nerve damage.92,157
Overall, studies of benign tumours reported 0–66% minor and
0% major complications. Patients treated for primary malig-
nant tumours presented higher complication ranges: 45–100%
minor and 0–28% major complications. Finally, patients with
metastatic tumours presented complication ranges similar to
the first group: 0–51% minor and 0–4% major complications.
The most frequently observed complications were mild skin
burn (also depending on operator skills), usually resolving by
1–2 weeks after FUS, and sonication pain during treatment
(also depending on anaesthesia choices). Major problems were
in large part due to lack of guidelines to protect normal
structures (e.g. there were eight serious nerve injuries, since
treatment guidelines did not limit proximity to nerves). Other
primary malignant studies implemented a 1-cm tumour margin
limit and major complications were limited to 8%. However,
MRgFUS produced only 4% (4/112) major complications in
patients with bone metastases. Overall, the data provide strong
evidence that FUS is safe for treatment of bone metastases and
primary benign lesions, whereas other applications are still under
investigation.75 Adverse events of extracorporeal USgHIFU ther-
apy were also reported.158,159
One last issue deserves special consideration: the use of contrast
agents before HIFU treatment. According to a recent study per-
formed by Hijnen et al,160 MRgHIFU treatment seems not in-
duce the dissociation of gadolinium (Gd)-diethylene-triamine-
penta-acetate. In small-tissue volumes, no significant effect on
the long-term in vivo Gd retention was found. However, care
must be taken with the use of proton resonance frequency shift-
based MR thermometry for HIFU guidance in combination with
Gd, since the susceptibility artefact induced by Gd can severely
influence treatment outcome.160
CLOSING REMARKS AND CONCLUSIONS
MRgFUS is an emerging technology which enhances the po-
tential efficacy of HIFU/FUS by influencing the accuracy of
treatment planning and monitoring (by using MRI). MRgFUS is
a completely non-invasive technique. The physician can cor-
rectly localize tumours or lesions, optimally deliver acoustic
energy (sonicate), monitor energy deposition in real time and
accurately control the deposited thermal dose.
The basic knowledge of running evidence in pre-clinical set-
ting helps to introduce physicians to this technology and to
enlighten MRgFUS users to new potential treatment strategies
and applications.
MRgFUS was approved and is gaining consensus for bone
metastases, other bone tumours and other applications in-
cluding degenerative disease. The core of the current program
for research and innovation of the European Union, “Horizon
2020”, is “active and healthy ageing”. This includes the impor-
tance of quality of life and the need for successful mini-invasive
therapy in order to postpone any major and invasive in-
tervention which may require long rehabilitation times, leading
to potential morbidity, mortality or needing revision. The
“palliative” role of any potential treatment approach in pain
relief while restoring better quality of life will be central in any
of the possible future scenarios of ageing. MRgFUS has been
demonstrated to be safe and effective in treating pain caused by
several medical conditions, and also to have more deep po-
tential in tumour ablation.
Although MRgFUS is still at the starting point, and several
limitations must be taken into consideration, it seems to be
a candidate to hold a prominent position in the next clinical
generation of therapeutic applications.
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